Data highlight safety profile of oral MS drug BG-12

Discuss Tecfidera (BG-12, dimethyl fumarate) as an oral treatment for multiple sclerosis.

Data highlight safety profile of oral MS drug BG-12

Postby MSUK » Tue Apr 24, 2012 8:21 am


The latest data on Biogen Idec Inc.'s (BIIB) experimental multiple-sclerosis pill BG-12 show "favorable safety and tolerability" that support the drug's use as a front-line treatment for MS patients, the biotechnology company said.

Details from the "Confirm" study on BG-12 were set for presentation at an American Academy of Neurology conference Tuesday. The drug is currently under review with U.S. and European regulators and could be approved early next year.
Positive data and high expectations for the MS treatment have helped drive Biogen shares to around all-time high levels recently. Most treatments for the chronic, inflammatory and potentially disabling disease are delivered by needle, but BG-12 is an oral drug that will likely be taken twice daily.

The Biogen-funded Confirm study of about 1,400 MS patients showed the most common side effects for BG-12 patients at two years were flushing, or reddening of the skin, and gastrointestinal issues such as diarrhoea and nausea. These problems were more common with BG-12 than they were with a placebo, but the side effects "decreased substantially" for BG-12 patients after the first month of treatment, the company said.... Read More - ... ageid/1679
User avatar
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 3:00 pm


Re: Data highlight safety profile of oral MS drug BG-12

Postby chrishasms » Tue Apr 24, 2012 12:46 pm

How much longer?
Family Elder
Posts: 1161
Joined: Thu Sep 14, 2006 3:00 pm

Return to Tecfidera (BG-12, dimethyl fumarate)


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service